Why are patients switching from compounded weight-loss drugs to Novo's Wegovy and Lilly's Foundayo pills?

Patients are switching because the lowest doses of Novo's oral Wegovy and Lilly's Foundayo cost around $149 per month—comparable to compounded versions and lower than their injectable counterparts (e.g., Wegovy injectable starts at $199, Zepbound at $299+), especially amid declining insurance coverage; doctors report patients explicitly asking to switch to the 'pharmaceutical-grade branded version' due to its affordability and FDA-approved status.

What key differences between Wegovy pills and Foundayo influence patient preference, according to doctors?

Doctors note Wegovy pills benefit from stronger brand recognition—as the same medicine and name as the established injectable—and have proven heart-protective data, increasing comfort for patients at cardiovascular risk; in contrast, Foundayo is perceived as newer and less familiar, with no heart-benefit data yet, causing hesitation among some patients despite its convenience.

ChemBrief

Topics Daily Digest Tags

Lower Cost Novo, Lilly Weight-Loss Pills Draw Patients from Compounded Drugs, Doctors Say

May 21, 2026

Novo Nordisk and Eli Lilly see patients switching to lower-priced oral weight-loss pills over compounded versions, expanding market access despite ongoing insurance coverage challenges.

reuters

2026-01-13

Jan. 13 Business Watch: Plants Close in Brazil and the UK; Lilly to Pay $1.2 Billion for Ventyx

2026-04-17

Lilly's obesity pill Foundayo gets 1,390 prescriptions in debut week

2026-04-19

Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

2026-04-24

Eli Lilly's Obesity Pill Records Modest Second Week as Battle with Novo Nordisk Intensifies

2026-04-30

S&P 500, Nasdaq On Course for Best Month Since 2020 Despite Middle East Risks